Treatment with GH receptor antagonist in acromegaly: Effect on cardiac arrhythmias

European Journal of Endocrinology

Volumn 168, Issue 1, 2013, Pages 15-22

  Auriemma, Renata S ^a   Pivonello, Rosario ^a   De Martino, Maria Cristina ^a   Cudemo, Giuseppe ^a   Grasso, Ludovica F S ^a   Galdiero, Mariano ^a   Perone, Ylenia ^a   Colao, Annamaria ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; OCTREOTIDE; PEGVISOMANT;

ACROMEGALY; ADULT; ARTICLE; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; CLINICAL TRIAL; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; ELECTROCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE MASS; HEART RATE; HEART VENTRICLE EXTRASYSTOLE; HUMAN; LONG TERM CARE; MALE; NEUROSURGERY; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RADIOTHERAPY; SHORT COURSE THERAPY; SUPRAVENTRICULAR PREMATURE BEAT; TREATMENT DURATION;

ACROMEGALY; ADULT; ARRHYTHMIAS, CARDIAC; FEMALE; HEART RATE; HUMAN GROWTH HORMONE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, SOMATOTROPIN;

EID: 84871886713     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-0596     Document Type: Article

References (34)

1. Melmed S. Acromegaly. New England Journal of Medicine 2006 355 2558-2573. (doi:10.1056/NEJMra062453)
2. Colao A, Ferone D, Marzullo P & Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocrine Reviews 2004 25 102-152. (doi:10.1210/er.2002-0022)
3. Nabarro JDN. Acromegaly. Clinical Endocrinology 1987 26 481-512. (doi:10.1111/j.1365-2265.1987.tb00805.x)
4. Wright AD, Hill DM, Lowy C & Russell-Fraser T. Mortality in acromegaly. Quarterly Journal of Medicine 1970 153 1-16.
5. Bengtsson B, Eden S, Ernest I, Oden A & Sjogren B. Epidemiology and long-term survival in acromegaly. Acta Medica Scandinavica 1988 223 327-335. (doi:10.1111/j.0954-6820.1988.tb15881.x)
6. Rajasoorya C, Holdaway IM,Wrightson P, Scott DJ & Ibbertson HK. Determinants of clinical outcome and survival in acromegaly. Clinical Endocrinology 1994 41 95-102. (doi:10.1111/j.1365-2265.1994.tb03789.x)
7. Orme SM, McNally RJQ, Cartwright RA & Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. Journal of Clinical Endocrinology and Metabolism 1998 83 2730-2734. (doi:10.1210/jc.83.8. 2730)
8. Thuesen L, Christensen SE, Weeke J, Orskov H & Henningsen P. A hyperkinetic heart in uncomplicated active acromegaly. Acta Medica Scandinavica 1988 223 337-343. (doi:10.1111/j.0954-6820.1988.tb15882.x)
9. Kahaly G, Olshausen KV, Mohr-Kahaly S, Erbel R, Boor S, Beyer J & Meyer J. Arrhythmias profile in acromegaly. European Heart Journal 1992 13 51-56.
10. Rodrigues EA, Caruana MP, Lahiri A, Nabarro JD, Jacobs HS & Raftery EB. Subclinical cardiac dysfunction in acromegaly: evidence for a specific disease of heart muscle. British Heart Journal 1989 62 185-194. (doi:10.1136/hrt.62.3.185)
11. Colao A, Pivonello R, Grasso LFS, Auriemma RS, Galdiero M, Savastano S & Lombardi G. Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study. European Journal of Endocrinology 2011 165 713-721. (doi:10.1530/EJE-11-0408)
12. Clayton RN. Cardiovascular function in acromegaly. Endocrine Reviews 2003 24 272-277. (doi:10.1210/er.2003-0009)
13. Fatti LM, Scacchi M, Lavezzi E, Pecori Giraldi F, De Martin M, Toja P, Michailidist G, Stramba-Badiale M & Cavagnini F. Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients. Clinical Endocrinology 2006 65 626-630. (doi:10.1111/j.1365-2265.2006.02639.x)
14. Montomoli C, Monti MC, Stramba-Badiale M, Marinoni A, Foglieni N, Carreri V, Amigoni M & Schwartz PJ. Mortality due to sudden infant death syndrome in Northern Italy, 1990-2000: a baseline for the assessment of prevention campaigns. Paediatric and Perinatal Epidemiology 2004 18 336-343. (doi:10.1111/j.1365-3016.2004.00583.x)
15. Colao A, Marzullo P, Ferone D, Spinelli L, Cuocolo A, Bonaduce D, Salvatore M, Boerlin V, Lancranjan I & Lombardi G. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. Journal of Clinical Endocrinology and Metabolism 2000 85 3132-3140. (doi:10.1210/jc.85.9. 3132)
16. Baldelli R, Ferretti E, Jaffrain-Rea ML, Iacobellis G, Minniti G, Caracciolo B, Moroni C, Cassone R, Gulino A & Tamburrano G. Cardiac effects of lanreotide, a slow release somatostatin analog in acromegalic patients. Journal of Clinical Endocrinology and Metabolism 1999 84 527-532. (doi:10.1210/jc.84.2.527)
17. Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Florimonte L, Salvatore M & Lombardi G. Effects of one-year treatment with octreotide on cardiac performance in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 1999 84 17-23. (doi:10.1210/jc.84.1.17)
18. Colao A, Pivonello R, Galderisi M, Cappabianca P, Auriemma RS, Galdiero M, Cavallo LM, Esposito F & Lombardi G. Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. Journal of Clinical Endocrinology and Metabolism 2008 23 2639-2646. (doi:10.1210/jc.2008-0299)
19. Pivonello R, Galderisi M, Auriemma RS, De Martino MC, Galdiero M, Ciccarelli A, D'Errico A, Kuorides I, Burman P, Lombardi G et al. Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. Journal of Clinical Endocrinology and Metabolism 2007 92 476-482. (doi:10.1210/jc.2006-1587)
20. Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ et al. Efficacy of 12-months of treatment with the GH receptor antagonist pagvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. European Journal of Endocrinology 2006 154 467-477. (doi:10.1530/eje.1.02112)
21. Foppa M, Duncan BB & Rohde LEP. Echocardiography-based left ventricular mass estimation. How should we define hypertrophy? Cardiovascular Ultrasound 2005 3 17. (doi:10.1186/1476-7120-3-17)
22. Lombardi G, Colao A, Marzullo P, Biondi B, Palmieri E, Fazio S & the Multicenter Italian Study Group on Lanreotide. Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-indiced GH and IGF-I decrease in acromegaly. A prospective multicenter study. Journal of Endocrinological Investigation 2002 25 971-976. (Pubitemid 36113282)
23. Smith WH, Nair RU, Adamson D, Kearney MT, Ball SG & Balmforth AJ. Somatostatin receptor subtypes expression in the human heart: differential expression by myocytes and fibroblasts. Journal of Endocrinology 2005 187 379-386. (doi:10.1677/joe.1.06082)
24. The University of Arizona Health Science Center. Center for Education and Research on Therapeutics. Drugs to be avoided by congenital long QT patients. 2002 www.QTdrugs.org.
25. Bubinski R, KUs W & Goch J. Effects of somatostatin on conduction system of the heart. Kardiologia Polska 1993 38 258-262. (Pubitemid 23125851)
26. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML et al. Long term treatment of acromegaly with pegvisomant, a growth hormone antagonist. Lancet 2001 358 1754-1759. (doi:10.1016/S0140-6736(01)06844-1)
27. Gidding SS, Carnethon MR, Daniels S, Liu K, Jacobs DR, Sidney S & Gardin J. Low cardiovascular risk is associated with favourable left ventricular mass, left ventricular relative wall thickness, and left atrial size: the CARDIA study. Journal of American Society of Echocardiography 2010 23 816-822. (doi:10.1016/j.echo.2010.05.023)
28. Shiozaki AA, Senra T, Arteaga E, Pita CG, Martinelli Filho M, Avila LF, Parga Filho JR, Mady C & Rochitte CE. Myocardial fibrosis in patients with hypertrophic cardiomyopathy and high risk for sudden death. Arquivos Brasileiros de Cardiologia 2010 94 502-506. (doi:10.1590/S0066-782X2010005000017)
29. Lie JT & Grossman SJ. Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients. American Heart Journal 1980 1 41-52. (doi:10.1016/0002-8703(80)90277-X)
30. Courville C & Mason VR. The heart in acromegaly. Archives of Internal Medicine 1938 61 704-713. (doi:10.1001/archinte.1938.00180100014002)
31. Hejtmancik MR, Bradfield JY & Herrmann GR. Acromegaly and heart: a clinical and pathologic study. Annals of Internal Medicine 1950 34 1445-1456.
32. Goldberg MB & Lisser H. Acromegaly: a consideration of its course and treatment. Report of four cases with autopsies. Journal of Clinical Endocrinology and Metabolism 1942 2 477-501. (doi:10.1210/jcem-2-8-477)
33. Bogazzi F, Di Bello V, Palagi C, Delle Donne MG, Di Cori A, Gavioli S, Talini E, Cosci C, Sardella C, Brogioni S et al. Improvement of intrinsic myocardial contractility and cardiac fibrosis degree in acromegalic patients treated with somatostatin analogues: a prospective study. Clinical Endocrinology 2005 62 590-596. (doi:10.1111/j.1365-2265.2005.02265.x)
34. Herrmann BL, Bruch C, Saller B, Ferdin S, Dagres N, Ose C, Erbel R & Mann K. Occurrence of ventricular late potentials in patients with active acromegaly. Clinical Endocrinology 2001 55 201-207. (doi:10.1046/j.1365-2265. 2001.01319.x)